Summary by Moomoo AI
WA-HUANG PHARMACEUTICALS AND XINDA BIO ANNOUNCED THAT THEIR JOINT DEVELOPMENT APPLICATION FOR A NEW CHINESE DRUG FOR FURUQUINITINE AND CINDYLIONE ANTIDOTE FOR THE TREATMENT OF LATE ENDOMETRIAL CANCER HAS BEEN ACCEPTED AND INCLUDED IN PRIORITY REVIEW BY THE NATIONAL DRUG ADMINISTRATION. This combination therapy was included in a breakthrough treatment line in July 2023 aimed at treating patients with disease progression both after systemic antitumor therapy. FRUSICA-1 is a Phase II clinical trial supporting this application and its data will be published at a recent academic conference. This marks an important step in reshaping the treatment landscape of this disease in China, said Dr. Shi Ming, head of research and development at Wah Wong Medicine. Dr. Zhou Fai of Shinda...Show More